Qrons (QRON) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Cover [Abstract]
Entity Registrant Name	QRONS INC.
Entity Central Index Key	0001689084
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		13,289,789
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-55800
Entity Incorporation State Country Code	WY
Entity Tax Identification Number	81-3623646
Entity Address Postal Zip Code	11101
Entity Address Address Line 1	28-10 Jackson Avenue #26N
Entity Address City Or Town	Long Island City
Entity Address State Or Province	NY
City Area Code	212
Local Phone Number	945-2080
Entity Interactive Data Current	Yes

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 8,467	$ 35,065
Total current assets	8,467	35,065
TOTAL ASSETS	8,467	35,065
Current liabilities
Accounts payable and accrued liabilities	131,517	90,976
Accounts payable and accrued liabilities - related party	30,842	38,192
Demand loans, related party	85,873	50,000
Advances from related party	348,500	286,000
Unsecured short-term advances	100,000	100,000
Convertible notes - related party	0	25,000
Convertible notes, net of debt discount	195,000	141,685
Derivative liabilities	336,172	405,957
Total current liabilities	1,227,904	1,137,810
Total liabilities	1,227,904	1,137,810
Stockholders' deficit
Series A Preferred stock: $0.001 par value; 10,000 shares authorized; 2,000 shares issued and outstanding	2	2
Common stock, $0.0001 par value: 100,000,000 shares authorized; 13,289,789 shares issued and outstanding	1,329	1,329
Additional paid-in capital	7,697,351	7,697,351
Accumulated deficit	(8,918,119)	(8,801,427)
Total stockholders' deficit	(1,219,437)	(1,102,745)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 8,467	$ 35,065

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
CONDENSED BALANCE SHEETS
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,289,789	13,289,789
Common stock, shares outstanding	13,289,789	13,289,789

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
CONDENSED STATEMENTS OF OPERATIONS (Unaudited)
Net sales	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development expenses	6,250	9,076	23,596	32,262
Professional fees	8,999	11,868	62,904	35,808
General and administrative expenses	7,202	9,363	30,571	43,398
Total operating expenses	22,451	30,307	117,071	111,468
Loss from operations	(22,451)	(30,307)	(117,071)	(111,468)
Other income (expense)
Interest expense	(6,875)	(43,526)	(69,406)	(166,270)
Change in fair market value of derivative liabilities	105,090	(6,047)	69,785	(2,877)
Total other income (expense)	98,215	(49,573)	379	(169,147)
Net income (loss)	$ 75,764	$ (79,880)	$ (116,692)	$ (280,615)
Net income (loss) per common share - basic	$ 0.01	$ (0.01)	$ (0.01)	$ (0.02)
Net income (loss) per common share - diluted	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted average shares outstanding
Basic	13,289,789	13,289,789	13,289,789	13,289,789
Diluted	18,761,704	17,737,367	18,761,704	17,737,367

CONDENSED STATEMENTS OF CHANGES

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT (Unaudited) - USD ($)	Total	Common Stock	Preferred Stock Series A [Member]	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2020		13,289,789	2,000
Balance, amount at Dec. 31, 2020	$ (694,316)	$ 1,329	$ 2	$ 7,037,796	$ (7,733,443)
Stock options granted to non-employees as research and development costs	3,100	0	0	3,100	0
Net loss for the period	(235,309)	$ 0	$ 0	0	(235,309)
Balance, shares at Mar. 31, 2021		13,289,789	2,000
Balance, amount at Mar. 31, 2021	(926,525)	$ 1,329	$ 2	7,040,896	(7,968,752)
Balance, shares at Dec. 31, 2020		13,289,789	2,000
Balance, amount at Dec. 31, 2020	(694,316)	$ 1,329	$ 2	7,037,796	(7,733,443)
Net loss for the period	(280,615)
Balance, shares at Sep. 30, 2021		13,289,789	2,000
Balance, amount at Sep. 30, 2021	(968,731)	$ 1,329	$ 2	7,043,996	(8,014,058)
Balance, shares at Mar. 31, 2021		13,289,789	2,000
Balance, amount at Mar. 31, 2021	(926,525)	$ 1,329	$ 2	7,040,896	(7,968,752)
Stock options granted to non-employees as research and development costs	3,100	0	0	3,100	0
Net loss for the period	34,574	$ 0	$ 0	0	34,574
Balance, shares at Jun. 30, 2021		13,289,789	2,000
Balance, amount at Jun. 30, 2021	(888,851)	$ 1,329	$ 2	7,043,996	(7,934,178)
Net loss for the period	(79,880)	$ 0	$ 0	0	(79,880)
Balance, shares at Sep. 30, 2021		13,289,789	2,000
Balance, amount at Sep. 30, 2021	(968,731)	$ 1,329	$ 2	7,043,996	(8,014,058)
Balance, shares at Dec. 31, 2021		13,289,789	2,000
Balance, amount at Dec. 31, 2021	(1,102,745)	$ 1,329	$ 2	7,697,351	(8,801,427)
Net loss for the period	(264,128)	$ 0	$ 0	0	(264,128)
Balance, shares at Mar. 31, 2022		13,289,789	2,000
Balance, amount at Mar. 31, 2022	(1,366,873)	$ 1,329	$ 2	7,697,351	(9,065,555)
Balance, shares at Dec. 31, 2021		13,289,789	2,000
Balance, amount at Dec. 31, 2021	(1,102,745)	$ 1,329	$ 2	7,697,351	(8,801,427)
Net loss for the period	(116,692)
Balance, shares at Sep. 30, 2022		13,289,789	2,000
Balance, amount at Sep. 30, 2022	(1,219,437)	$ 1,329	$ 2	7,697,351	(8,918,119)
Balance, shares at Mar. 31, 2022		13,289,789	2,000
Balance, amount at Mar. 31, 2022	(1,366,873)	$ 1,329	$ 2	7,697,351	(9,065,555)
Net loss for the period	71,672	$ 0	$ 0	0	71,672
Balance, shares at Jun. 30, 2022		13,289,789	2,000
Balance, amount at Jun. 30, 2022	(1,295,201)	$ 1,329	$ 2	7,697,351	(8,993,883)
Net loss for the period	75,764	$ 0	$ 0	0	75,764
Balance, shares at Sep. 30, 2022		13,289,789	2,000
Balance, amount at Sep. 30, 2022	$ (1,219,437)	$ 1,329	$ 2	$ 7,697,351	$ (8,918,119)

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows From Operating Activities
Net loss	$ (116,692)	$ (280,615)
Adjustments to reconcile net loss to net cash used by operating activities:
Stock options issued for research and development expense	0	6,200
Non cash interest	0	94,332
Accretion of debt discount	53,315	60,269
Change in fair market value of derivative liabilities	(69,785)	2,877
Changes in operating assets and liabilities:
(Increase) in prepaid expenses	0	(2,000)
Increase in accounts payable and accrued liabilities	40,541	22,399
(Decrease) increase in accounts payable and accrued liabilities, related party	3,523	(3,920)
Net cash used by operating activities	(89,098)	(100,458)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities	0	0
Cash Flows From Financing Activities
Advances from related party	62,500	0
Proceeds from convertible note	0	100,000
Net cash provided from financing activities	62,500	100,000
Decrease in cash and cash equivalents	(26,598)	(458)
Cash at beginning of year	35,065	57,632
Cash at end of period	8,467	57,174
SUPPLEMENTAL DISCLOSURES
Interest paid	0	0
Income taxes paid	0	0
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Convertible notes - related party modified to 6% promissory note	25,000	0
Accrued interest payable - related party convertible note modified to 6% promissory note	10,873	0
Derivative liability associated with debt discount	0	51,009
Derivative liability associated with warrants	$ 0	$ 143,323

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Description of Business and Basis of Presentation
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Organization and Nature of Business: Qrons Inc. (“Qrons” or the “Company”) was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. and changed its name to Qrons Inc., effective August 8, 2017. The Company’s common stock was approved by the Financial Industry Regulatory Authority (“FINRA”) for quotation on the OTC pink sheets under the symbol “BLMB” as of July 3, 2017. FINRA announced the Company’s name change to Qrons Inc. on August 9, 2017. The new name and symbol change to “QRON” for the OTC Market was effective August 10, 2017. The Company’s common stock commenced trading on the OTCQB Venture Market on August 12, 2019. The Company is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal diseases, which are an enormous social and economic burden on society. The Company seeks to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. The Company’s search is currently focused on researchers based in Israel, a country which is world-renowned for biotech innovations and where its President is located and where its research to date has been conducted. The Company’s principal executive office is located at 28-10 Jackson Avenue, Long Island City, #26N, New York 11101.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Financial Statements: In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Fiscal year end: Use of Estimates: Cash Equivalents: Research and Development Costs: Research and Development Advertising and Marketing Costs: Related Parties: Stock Based Compensation and Other Share-Based Payments: Compensation - Stock Compensation Fair Value of Financial Instruments ASC 820, Fair Value Measurements Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of September 30, 2022 and December 31, 2021: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of September 30, 2022: Liabilities Derivative liabilities $ - $ - $ 336,172 As of December 31, 2021: Liabilities Derivative liabilities $ - $ - $ 405,957 Warrants: Derivatives and Hedging Income taxes: Income Taxes Basic and Diluted Loss Per Share Earnings Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The table below reflects the potentially dilutive securities outstanding during each reporting period: Nine Months Ended September 30, 2022 2021 Research warrants at 3% of issued and outstanding shares 398,694 398,694 Convertible notes 593,637 568,184 Series A preferred shares 700 700 Stock options vested 4,048,332 3,185,000 Stock purchase warrants 295,000 295,000 Total 5,336,363 4,447,578 New Accounting Pronouncements:

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2022
Going Concern
Going Concern	Note 3 – Going Concern The Company has experienced net losses to date and has not generated revenues from operations. While the Company raised proceeds of $100,000 during the year ended December 31, 2021 through the issuance of a convertible promissory note, and a further $62,500 in unsecured advances from related parties in the current nine months ended September 30, 2022, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the fourth quarter of 2022. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing, and continued support from its officers and directors. There can be no assurance that financing, whether debt or equity, will be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. In addition, if the Company is unable to obtain adequate financing due to the continued effect of COVID-19 on the capital markets, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty. Covid-19 Pandemic The COVID-19 pandemic has had an adverse impact on the research and development of our product candidates. Research facilities at Dartmouth were subject to closures as well as laboratories at Ariel in Israel during fiscal 2020. This resulted in our discontinuing our research at these universities and was part of our decision to adjust our research to be collaborative and to seek aligning with third parties to advance our expanded goals. COVID-19 also caused significant disruptions to the global financial markets, which severely impacted our ability to raise additional capital. We terminated our employees in April 2020 in an effort to conserve resources as we evaluated our business development efforts. We may be required to further reduce operations or cease operations if we are unable to finance our operations. We remain unable to predict with certainty the ongoing effects of the COVID-19 pandemic on future operations, as well as the actions of governments, and when and to what extent normal economic and operating conditions will return to pre-pandemic levels. Even as the COVID-19 pandemic has subsided, we continue to experience adverse impacts to our business, including delays on the successful raising of additional capital.

Convertible Note - Related Part

Convertible Note - Related Party and Derivative Liabilities	9 Months Ended
	Sep. 30, 2022
Convertible Note - Related Party and Derivative Liabilities
Convertible Note - Related Party and Derivative Liabilities	Note 4 – Convertible Note – Related Party and Derivative Liabilities On September 1, 2016, the Company entered into a convertible debenture agreement with Decagon LLC, doing business as CubeSquare, LLC (“CubeSquare”), of which the Company’s Chief Executive Officer is the managing partner and its President is a 25% owner of CubeSquare. The Company received proceeds of $10,000 during fiscal 2016 (“Note 1”). Note 1 bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender’s option, in cash or common stock. Any portion of the loan and unpaid interest is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender. On September 29, 2017, the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018; on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019; on November 6, 2019, the Company further amended Note 1 to extend the maturity date to September 1, 2020; on October 30, 2020, the Company further amended Note 1 to extend the maturity date to September 1, 2021; and on October 7, 2021, the Company further amended Note 1 to extend the maturity date to September 1, 2022 under the same terms and conditions. On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and was due on September 27, 2018. Interest accrues from September 27, 2017 and is payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. On September 9, 2018, Note 2 was amended to extend the maturity date to September 27, 2019. On November 6, 2019, Note 2 was amended to extend the maturity date to September 27, 2020; on October 30, 2020 Note 2 was amended to extend the maturity date to September 27, 2021; and further on October 7, 2021 Note 2 was amended to extend the maturity date to September 27, 2022. On September 27, 2022 the Board and the noteholder agreed to cancel the two convertible notes and in full satisfaction of such outstanding debt to issue a new 6% promissory note to CubeSquare in the principal amount of $35,873, representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022. The Company analyzed the amendment to Note 1 and Note 2 under ASC 815-10-15-83 and concluded that the conversion feature within these two convertible Notes meet the definition of a derivative. The Company estimated the fair value of the derivative at each report date using the Black-Scholes valuation model to value the derivative liability related to the variable conversion rate. The carrying value of these convertible notes is as follows: September 30, 2022 December 31, 2021 Face value of certain convertible notes $ 25,000 $ 25,000 Convertible notes extinguish (25,000 ) - Carrying value $ - $ 25,000 For Three Months Ended September 30, For Nine Months Ended September 30, 2022 2021 2022 2021 Interest on the convertible notes $ 432 $ 504 $ 1,424 $ 1,510 As of September 30, 2022 and December 31, 2021, the unpaid interest balance under Accounts payable and accrued liabilities – related party was $0 and $9,449, respectively. As a result of the application of ASC 815, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Balance at December 31, 2020 $ 61,682 Change in fair value 11,417 Balance at December 31, 2021 73,099 Change in fair value (73,099 ) Balance at September 30, 2022 $ - The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of September 27, 2022 and December 31, 2021 and the commitment date: Commitment Date December 31, 2021 September 27, 2022 Expected dividends 0 0 0 Expected volatility 101% ~103 % 181% ~ 182 % 101.56 % Expected term 0.92 ~ 1 year 0.67 ~ 0.74 year 0.00 year Risk free interest rate 1.33 % 1.06 % 2.22 %

Convertible Note and Derivative

Convertible Note and Derivative Liabilities	9 Months Ended
	Sep. 30, 2022
Convertible Note and Derivative Liabilities
Convertible Note and Derivative Liabilities	Note 5 – Convertible Note and Derivative Liabilities (1) 8% Convertible notes with warrants issued in December 2019 and February 2020 In December 2019, we issued and sold in a private offering 8% convertible notes in the aggregate principal amount of $70,000. Such notes were due on December 31, 2021 and are convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00. On February 19, 2020 we issued and sold in a private offering an 8% convertible note in the principal amount of $10,000. The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 10,000 shares of common stock at an exercise price of $1.00. The carrying value of these convertible notes is as follows: September 30, 2022 December 31, 2021 Face value of certain convertible notes $ 80,000 $ 80,000 Less: unamortized discount - (541 ) Carrying value $ 80,000 $ 79,459 Interest expenses associated with the convertible notes are as follows: For Three Months Ended September 30, For Nine Months Ended September 30, 2022 2021 2022 2021 Interest on the convertible notes $ 1,613 $ 1,916 $ 4,787 $ 4,485 Amortization of debt discount - 9,029 541 26,793 Total $ 1,613 $ 10,945 $ 5,328 $ 31,278 As of September 30, 2022 and December 31, 2021, the unpaid interest balance under Accounts payable and accrued liabilities was $17,656 and $12,869, respectively. The convertible notes qualify for derivative accounting and bifurcation under ASC 815. The derivative liability of the $80,000 convertible notes was calculated using the Black-Scholes pricing model to be $72,689. As a result of the application of ASC 815, as of September 30, 2022 and December 31, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Balance at December 31, 2020 $ 92,803 Change in fair value 64,687 Balance at December 31, 2021 157,490 Change in fair value (131,036 ) Balance at September 30, 2022 $ 26,454 The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of September 30, 2022 and December 31, 2021 and the commitment date: Commitment Date December 31, 2021 September 30, 2022 Expected dividends 0 0 0 Expected volatility 154% ~173 % 203% ~ 301 % 95% ~ 101 % Expected term 2.10 years 1.08 ~ 1.22 years 0.25 ~ 0.39 years Risk free interest rate 1.42 ~ 1.65% 0.39 % 3.33 % (2) 8% Convertible note with warrants issued on June 15, 2021 On June 15, 2021, the Company entered into a note purchase agreement with Quick Capital, LLC (“Quick Capital”) pursuant to which the Company issued a twelve-month convertible promissory note in the principal amount of $115,000 for a $100,000 investment (the “Quick Note”), which included an original issuance discount of 10% and a $3,500 credit for legal and transaction costs. In connection with the Quick Note issuance, Quick Capital was also issued a five-year warrant (the “Quick Warrant”) to purchase up to an aggregate of 115,000 shares of the Company’s common stock at an exercise price of $1.00 per share (the “Quick Warrant Shares”) subject to adjustments for dilutive issuances at lower prices. The Quick Note is convertible into shares of common stock at a conversion price of $0.50 per share. If delivery of the conversion shares is not timely made, the Company is obligated to pay Quick Capital $2,000 for each day that the delivery is late as liquidated damages. The conversion price of the Quick Note will be reduced if the Company issues common stock or grants derivative securities for consideration at a price less than the conversion price to the amount of the consideration of such dilutive issuance. The Quick Note may not be prepaid. The Company is subject to significant cash penalties if the Company defaults on the Quick Note or in the event shares are not issued timely when a notice of conversion is provided. If an event of default occurs, the Quick Note will become immediately due and payable in an amount equal to 150% of the then outstanding principal amount of the Quick Note plus any interest or amounts owing to Quick Capital. The default provisions are based on the type of default and include a penalty of 50% of the principal plus accrued interest due (the “Default Sum”) and a parity value of the Default Sum based on the effective conversion of the Quick Note on the date of payment of the default and the maximum stock value during the period between the default date and the payment date. The Company valued the embedded default derivative liability of the Quick Note and the Quick Warrant liability, including the full ratchet reset feature, using Monte Carlo models. While the Company has not received a notice of default, the Quick Note matured on June 15, 2022, and the fair value of the Quick Note and Quick Warrant embedded default derivatives liability has been valued as of September 30, 2022. The carrying value of the Quick Note is as follows: September 30, 2022 December 31, 2021 Face value of Quick Note $ 115,000 $ 115,000 Less: unamortized discount - (52,774 ) Carrying value $ 115,000 $ 62,226 Interest expenses associated with the conversion feature is as follows: For Three Months Ended September 30, For Nine Months Ended September 30, 2022 2021 2022 2021 Interest on Quick Note $ 2,319 $ 2,319 $ 6,881 $ 2,697 Day one loss associated with derivatively liability - - - 79,332 Amortization of debt discount - 28,750 52,774 33,476 Total $ 2,319 $ 31,069 $ 59,655 $ 115,505 As a result of the application of ASC 815 as of September 30, 2022 and December 31, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Derivative liability associated with convertible note on commitment date $ 51,009 Derivative liability associated with warrants on commitment date 143,323 Change in fair value – convertible note (21,597 ) Change in fair value – warrants 2,633 Balance at December 31, 2021 175,368 Change in fair value – convertible note 52,035 Change in fair value – warrants 82,315 Balance at September 30, 2022 $ 309,718 The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of September 30, 2022 and December 31, 2021 and the commitment date: Convertible note: Commitment Date December 31, 2021 September 30, 2022 Expected dividends 0 0 0 Expected volatility 307.10 % 215.70 % 101.40 % Expected term 1 years 0.45 years 0.00 years Risk free interest rate 0.18 % 0.43 % 1.28 % Warrants: Commitment Date December 31, 2021 September 30, 2022 Expected dividends 0 0 0 Expected volatility 201.70 % 200.90 % 208.90 % Expected term 5 years 4.45 years 3.7 years Risk free interest rate 0.65 % 0.82 % 3.760 %

Unsecured Short-Term Advance fr

Unsecured Short-Term Advance from Third Party	9 Months Ended
	Sep. 30, 2022
Unsecured Short-Term Advance from Third Party
Unsecured Short-Term Advance from Third Party	Note 6 – Unsecured Short-Term Advance from Third Party On June 20, 2019, the Company received $100,000 from a third party in the form of an unsecured, demand, non-interest-bearing, short-term advance to meet its operating needs. The advance remains outstanding at September 30, 2022 and December 31, 2021.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions
Related Party Transactions	Note 7 – Related Party Transactions (1) Demand Loan from related party On May 1, 2019, the Company issued a promissory note (the “Note”) to CubeSquare in the principal amount of $50,000. The Company’s Chief Executive Officer is the managing partner and the Company’s President is a 25% owner of CubeSquare. The Note bears interest at the rate of 8% per annum and is due and payable by the Company upon demand from CubeSquare. The Company recorded interest expenses of $997 and $2,981 for the three and nine months ended September 30, 2022 and recorded interest expenses of $1,008 and $2,991 for the three and nine months ended September 30, 2021. On September 27, 2022 the Board and the related party noteholder agreed to cancel two convertible notes issued to Cubesquare and in full satisfaction of such outstanding debt to issue a new 6% promissory note (Ref: Note 4) in the principal amount of $35,873, representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022. The Company recorded interest expenses of $17 and $17 for the three and nine months ended September 30, 2022 in respect to the new note. As of September 30, 2022 and December 31, 2021, the unpaid interest balance under Accounts payable and accrued liabilities – related party in respect of the aforementioned notes was $13,672 and $10,674, respectively. (2) Advances from Related Parties During the year ended December 31, 2019, the Company received $135,000 from Jonah Meer, its Chief Executive Officer, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $70,000 from Jonah Meer. An additional $62,500 in advances was received from Mr. Meer during the nine months ended September 30, 2022. Mr. Meer is owed $267,500 and $205,000 in respect to these advances at September 30, 2022 and December 31, 2021, respectively. On August 20, 2019, the Company received $50,000 from Ido Merfeld, its President, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $21,000 from Ido Merfeld. There were no additional advances from Mr. Merfeld during the nine months ended September 30, 2022, as well as during the year ended December 31, 2021. Mr. Merfeld is owed $71,000 in respect to these advances at September 30, 2022 and December 31, 2021. During the year ended December 31, 2020, the Company received $10,000 from CubeSquare in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs which amount is outstanding as of September 30, 2022 and December 31, 2021. (3) Others Jonah Meer, the Company’s Chief Executive Officer, made payments to various vendors during the years ended December 31, 2020 and 2019. During the nine months ended September 30, 2022 and during the year ended December 31, 2021, the Company repaid $900 and $11,575, respectively, of these advances leaving a balance payable to Mr. Meer of $16,000 at September 30, 2022 (December 31, 2021 - $16,900), which amount is reflected in accounts payable, related party. During the year ended December 31, 2019, Ido Merfeld, the Company’s President, made payments to various vendors in the aggregate amount of $1,169. The balance payable to Mr. Merfeld of $1,169 is reflected in accounts payable, related party as of September 30, 2022 and December 31, 2021.

Intellectual Property License A

Intellectual Property License Agreement and Sponsored Research Agreement	9 Months Ended
	Sep. 30, 2022
Intellectual Property License Agreement and Sponsored Research Agreement
Intellectual Property License Agreement and Sponsored Research Agreement	Note 8 – Intellectual Property License Agreement and Sponsored Research Agreement Dartmouth College – Intellectual Property License Agreement On October 2, 2019, the Company entered into an intellectual property license agreement (the “Intellectual Property License Agreement”) pursuant to which Dartmouth granted the Company an exclusive world-wide license under the patent application entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services. The license grant includes the right of the Company to sublicense to third parties subject to the terms of the Agreement. The Agreement provided for: (i) a $25,000 license issue fee; (ii) an annual license maintenance fee of $25,000, until the first commercial sale of a licensed product or service; (iii) an earned royalty of 2% of net sales of licensed products and services by the Company or a sublicensee; (iv) 15% of consideration received by the Company under a sublicense; and (v) beginning in the first calendar year after the first commercial sale, an annual minimum royalty payment of $500,000, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter. The Company will also reimburse Dartmouth for all patent preparation, filing, maintenance and defense costs. Failure to timely make any payment due under the Agreement will result in interest charges to the Company of the lower of 10% per year or the maximum amount of interest allowable by applicable law. The Agreement may be terminated by Dartmouth if the Company is in material breach of the Agreement which is not cured after 30 days of notice thereof or if the Company becomes insolvent. Dartmouth may terminate the Agreement if the Company challenges a Dartmouth patent or does not terminate a sublicensee that challenges a Dartmouth patent, except in response to a valid court or governmental order. The Company may terminate the Agreement at any time upon six months written notice to Dartmouth. If the Company or any sublicensee or affiliate institutes or participates in a licensed patent challenge, the then current earned royalty rate for licensed products covered by Dartmouth patents will automatically be increased to three times the then current earned royalty rate. On March 23, 2021, the United States Patent and Trademark Office issued U.S. Patent No. 10,954,315 to the Trustees of Dartmouth College, which is directed to mechanically interlocked, molecules-based materials for 3-D printing. The patent’s inventors are Professor Chenfeng Ke, a member of the Company’s Scientific Advisory Board and Qianming Lin, Professor Ke’s assistant. The patent grant is the culmination of the Intellectual Property License Agreement between the Company and Dartmouth with respect to an exclusive world-wide license of intellectual property related to 3D printable materials in the fields of human and animal health. Dartmouth College – Intellectual Property License Agreement The Company expensed $18,750 as license fees during each of the nine months ended September 30, 2022 and 2021 with respect to such annual fee.

Stock Plan

Stock Plan	9 Months Ended
	Sep. 30, 2022
Stock Plan
Stock Plan	Note 9 – Stock Plan 2016 Stock Option and Stock Award On December 14, 2016, the Board adopted the Company’s 2016 Stock Option and Stock Award Plan (the “Plan”). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Board. The Company has reserved 10 million shares for issuance under the Plan. (a) Stock Options granted to Science Advisors and Business Advisors On February 10, 2020 under the Plan, the Company granted three-year options to purchase an aggregate of 50,000 shares of its common stock at an exercise price of $2.00 per share, to a Business Advisor. 25,000 of such shares subject to the option were immediately exercisable and expire on February 10, 2023, and 25,000 shares vest on February 10, 2021 and expire on February 10, 2024. On July 15, 2020, 25,000 unvested options were forfeited. In January 2021, 25,000 vested options were forfeited. (b) Stock Options granted to Employees: On December 10, 2018, the Board awarded an employee the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise. On March 23, 2020, the Company accelerated the vesting provision to provide for the immediate vesting of such options. 33,333 of such shares subject to the option were forfeited unexercised on December 10, 2021. The remaining option expires on March 23, 2023. On December 10, 2019, the Board awarded an employee, the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2021 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise. On March 23, 2020, the Company accelerated the vesting provision to provide for the immediate vesting of such options. Such options expire on March 23, 2023. On December 10, 2020, under the Plan, the Board awarded an employee, an immediately exercisable three-year stock option to purchase 100,000 shares of the common stock of the Company at an exercise price of $2.00 per share. On December 22, 2021, under the Plan, the Board awarded an employee, an immediately exercisable three-year stock option to purchase 325,000 shares of the common stock of the Company at an exercise price of $2.00 per share. On April 16, 2022, a three-year stock option to purchase 10,000 shares of common stock of the Company granted to a Science Advisor expired unexercised. On July 1, 2022, a three-year stock option to purchase 33,334 shares of common stock of the Company granted to a Science Advisor expired unexercised. On August 15, 2022, a three-year stock option to purchase 6,666 shares of common stock of the Company granted to a Science Advisor expired unexercised. The following table is the recognized compensation in respect of the above stock option compensation ((a) and (b)) which amount has been allocated as below: Three Months ended Nine Months ended September 30, September 30, 2022 2021 2022 2021 Research and development expenses $ - $ - $ - $ 6,200 As of September 30, 2022 and December 31, 2021, there was no unrecognized compensation remaining to be recognized in future periods. (c) Stock Options granted to Officers: On June 25, 2019, the Company appointed John N. Bonfiglio, PhD as its chief operating officer, effective July 1, 2019. As compensation, Dr. Bonfiglio was granted a three-year stock option to purchase 100,000 shares of common stock at an exercise price of $2.00 per share, 50,000 of which shares vested upon grant and 25,000 shares vested on each of July 1, 2020 and July 1, 2021, provided Dr. Bonfiglio was in the employ of the Company on such dates. Mr. Bonfiglio was terminated as chief operating officer as of November 30, 2019. Accordingly, all unvested stock options terminated on such date. In January 2021, 50,000 vested options were forfeited. On December 10, 2020, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share and are immediately exercisable. On December 22, 2021, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share and are immediately exercisable. A summary of the activity for the Company’s stock options at September 30, 2022 and December 31, 2021, is as follows: September 30, 2022 December 31, 2021 Weighted Average Exercise Weighted Average Remaining Contractual Life Weighted Average Exercise Weighted Average Remaining Contractual Life Shares Price (in years) Shares Price (in years) Outstanding, beginning of period 4,098,332 $ 2 3.08 3,276,666 $ 1.98 3.28 Granted - - - 975,000 $ 2 - Exercised - - - - $ - - Canceled/forfeited (50,000 ) $ - - (153,334 ) $ 2 - Outstanding, end of period 4,048,332 $ 2 2.29 4,098,332 $ 2 3.08 Options exercisable, end of period 4,048,332 $ 2 2.29 4,098,332 $ 2 3.08 Weighted average fair value of options granted $ 2 $ 1.98

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2022
Capital Stock
Capital Stock	Note 10 – Capital Stock Authorized: The Company has authorized 100,000,000 shares of common stock, par value $0.0001, and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001. Series A Preferred Stock: The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the “Stated Value”). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company’s common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding. There were 2,000 shares of Series A Preferred Stock issued and outstanding as of September 30, 2022 and December 31, 2021. Common Stock There were 13,289,789 shares of common stock issued and outstanding as of September 30, 2022 and December 31, 2021. Common Stock Purchase Warrants As of September 30, 2022 and December 31, 2021, the following common stock purchase warrants were outstanding: Warrants Weighted Average Exercise Price Outstanding – December 31, 2020 180,000 $ 1.00 Granted 115,000 (1) 1.00 Canceled/forfeited - - Exercised - - Outstanding – December 31, 2021 295,000 1.00 Granted - - Canceled/forfeited - - Exercised - - Outstanding – September 30, 2022 295,000 $ 1.00 (1) On June 15, 2021, the Company granted a convertible noteholder a warrant to purchase 115,000 shares of common stock at an exercise price of $1.00, subject to adjustments for full ratchet resets for dilutive issuances at lower prices. (See Note 5(2) above.)

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events
Subsequent Events	Note 11 – Subsequent Events The Company has evaluated events for the period through the date of the issuance of these financial statements and determined that there are no additional events requiring disclosure.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Summary of Significant Accounting Policies (Policies)
Financial Statements	Financial Statements: In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Fiscal Year End	Fiscal year end:
Use of Estimates	Use of Estimates:
Cash Equivalents	Cash Equivalents:
Research and Development Costs	Research and Development Costs: Research and Development
Advertising and Marketing Costs	Advertising and Marketing Costs:
Related Parties	Related Parties:
Stock Based Compensation and Other Share-Based Payments	Stock Based Compensation and Other Share-Based Payments: Compensation - Stock Compensation
Fair Value of Financial Instruments	ASC 820, Fair Value Measurements Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of September 30, 2022 and December 31, 2021: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of September 30, 2022: Liabilities Derivative liabilities $ - $ - $ 336,172 As of December 31, 2021: Liabilities Derivative liabilities $ - $ - $ 405,957
Warrants	Warrants: Derivatives and Hedging
Income taxes	Income taxes: Income Taxes
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Earnings Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The table below reflects the potentially dilutive securities outstanding during each reporting period: Nine Months Ended September 30, 2022 2021 Research warrants at 3% of issued and outstanding shares 398,694 398,694 Convertible notes 593,637 568,184 Series A preferred shares 700 700 Stock options vested 4,048,332 3,185,000 Stock purchase warrants 295,000 295,000 Total 5,336,363 4,447,578
New Accounting Pronouncements	New Accounting Pronouncements:

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Summary of Significant Accounting Policies (Policies)
Fair value of the Company's derivative liabilities	Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of September 30, 2022: Liabilities Derivative liabilities $ - $ - $ 336,172 As of December 31, 2021: Liabilities Derivative liabilities $ - $ - $ 405,957
Potentially dilutive securities at each reporting period	Nine Months Ended September 30, 2022 2021 Research warrants at 3% of issued and outstanding shares 398,694 398,694 Convertible notes 593,637 568,184 Series A preferred shares 700 700 Stock options vested 4,048,332 3,185,000 Stock purchase warrants 295,000 295,000 Total 5,336,363 4,447,578

Convertible Note Related Party

Convertible Note Related Party and Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Convertible Note Related Party and Derivative Liabilities (Tables)
The carrying value of these convertible notes is as follows	September 30, 2022 December 31, 2021 Face value of certain convertible notes $ 25,000 $ 25,000 Convertible notes extinguish (25,000 ) - Carrying value $ - $ 25,000 For Three Months Ended September 30, For Nine Months Ended September 30, 2022 2021 2022 2021 Interest on the convertible notes $ 432 $ 504 $ 1,424 $ 1,510
Schedule of derivative liability associated with the conversion	Balance at December 31, 2020 $ 61,682 Change in fair value 11,417 Balance at December 31, 2021 73,099 Change in fair value (73,099 ) Balance at September 30, 2022 $ -
Derivative liabilities were based upon the following management assumptions	Commitment Date December 31, 2021 September 27, 2022 Expected dividends 0 0 0 Expected volatility 101% ~103 % 181% ~ 182 % 101.56 % Expected term 0.92 ~ 1 year 0.67 ~ 0.74 year 0.00 year Risk free interest rate 1.33 % 1.06 % 2.22 %

Convertible Note and Derivati_2

Convertible Note and Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Convertible Note and Derivative Liabilities (Tables)
Carrying value of these convertible notes	September 30, 2022 December 31, 2021 Face value of certain convertible notes $ 80,000 $ 80,000 Less: unamortized discount - (541 ) Carrying value $ 80,000 $ 79,459
Interest expenses associated with the convertible notes	For Three Months Ended September 30, For Nine Months Ended September 30, 2022 2021 2022 2021 Interest on the convertible notes $ 1,613 $ 1,916 $ 4,787 $ 4,485 Amortization of debt discount - 9,029 541 26,793 Total $ 1,613 $ 10,945 $ 5,328 $ 31,278
Fair value of the derivative liability associated with the conversion feature	Balance at December 31, 2020 $ 92,803 Change in fair value 64,687 Balance at December 31, 2021 157,490 Change in fair value (131,036 ) Balance at September 30, 2022 $ 26,454
Commitment and re-measurement dates	Commitment Date December 31, 2021 September 30, 2022 Expected dividends 0 0 0 Expected volatility 154% ~173 % 203% ~ 301 % 95% ~ 101 % Expected term 2.10 years 1.08 ~ 1.22 years 0.25 ~ 0.39 years Risk free interest rate 1.42 ~ 1.65% 0.39 % 3.33 %
Carrying value of the quick note	September 30, 2022 December 31, 2021 Face value of Quick Note $ 115,000 $ 115,000 Less: unamortized discount - (52,774 ) Carrying value $ 115,000 $ 62,226
Interest expenses associated with the conversion	For Three Months Ended September 30, For Nine Months Ended September 30, 2022 2021 2022 2021 Interest on Quick Note $ 2,319 $ 2,319 $ 6,881 $ 2,697 Day one loss associated with derivatively liability - - - 79,332 Amortization of debt discount - 28,750 52,774 33,476 Total $ 2,319 $ 31,069 $ 59,655 $ 115,505
Fair value of the derivative liability associated with the conversion feature is summarized as follows	Derivative liability associated with convertible note on commitment date $ 51,009 Derivative liability associated with warrants on commitment date 143,323 Change in fair value – convertible note (21,597 ) Change in fair value – warrants 2,633 Balance at December 31, 2021 175,368 Change in fair value – convertible note 52,035 Change in fair value – warrants 82,315 Balance at September 30, 2022 $ 309,718
Fair value at the commitment and re-measurement dates for the Company's derivative liabilities	Convertible note: Commitment Date December 31, 2021 September 30, 2022 Expected dividends 0 0 0 Expected volatility 307.10 % 215.70 % 101.40 % Expected term 1 years 0.45 years 0.00 years Risk free interest rate 0.18 % 0.43 % 1.28 % Warrants: Commitment Date December 31, 2021 September 30, 2022 Expected dividends 0 0 0 Expected volatility 201.70 % 200.90 % 208.90 % Expected term 5 years 4.45 years 3.7 years Risk free interest rate 0.65 % 0.82 % 3.760 %

Stock Plan (Tables)

Stock Plan (Tables)	9 Months Ended
	Sep. 30, 2022
Stock Plan
Recognized compensation in respect of the above stock option compensation allocated as general and administrative expenses	Three Months ended Nine Months ended September 30, September 30, 2022 2021 2022 2021 Research and development expenses $ - $ - $ - $ 6,200
Summary of the activity for the Company's stock options	September 30, 2022 December 31, 2021 Weighted Average Exercise Weighted Average Remaining Contractual Life Weighted Average Exercise Weighted Average Remaining Contractual Life Shares Price (in years) Shares Price (in years) Outstanding, beginning of period 4,098,332 $ 2 3.08 3,276,666 $ 1.98 3.28 Granted - - - 975,000 $ 2 - Exercised - - - - $ - - Canceled/forfeited (50,000 ) $ - - (153,334 ) $ 2 - Outstanding, end of period 4,048,332 $ 2 2.29 4,098,332 $ 2 3.08 Options exercisable, end of period 4,048,332 $ 2 2.29 4,098,332 $ 2 3.08 Weighted average fair value of options granted $ 2 $ 1.98

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2022
Capital Stock
Stock purchase warrants outstanding	Warrants Weighted Average Exercise Price Outstanding – December 31, 2020 180,000 $ 1.00 Granted 115,000 (1) 1.00 Canceled/forfeited - - Exercised - - Outstanding – December 31, 2021 295,000 1.00 Granted - - Canceled/forfeited - - Exercised - - Outstanding – September 30, 2022 295,000 $ 1.00

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Inputs, Level 1 [Member]
Liabilities
Derivative liabilities	$ 0	$ 0
Fair Value, Inputs, Level 2 [Member]
Liabilities
Derivative liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities
Derivative liabilities	$ 336,172	$ 405,957

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Total	5,336,363	4,447,578
Research Warrants [Member]
Total	398,694	398,694
Convertible Debt Securities [Member]
Total	593,637	568,184
Series A Preferred Shares [Member]
Total	700	700
Stock Options Vested [Member]
Total	4,048,332	3,185,000
Stock Purchase Warrants [Member]
Total	295,000	295,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Summary of Significant Accounting Policies (Policies)
Research and development costs	$ 6,250	$ 9,076	$ 23,596	$ 32,262

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Going Concern (Details Narrative)
Advances from related parties, unsecured	$ 62,500	$ 0
Proceeds from convertible note	$ 0	$ 100,000	$ 100,000

Convertible Note Related Part_2

Convertible Note Related Party and Derivative Liabilities (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Face value of certain convertible notes	$ 115,000	$ 115,000
Carrying value	115,000	62,226
Related Party Debt [Member]
Face value of certain convertible notes	25,000	25,000
Convertible notes extinguish	(25,000)	0
Carrying value	$ 0	$ 25,000

Convertible Note Related Part_3

Convertible Note Related Party and Derivative Liabilities (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Related Party Debt [Member]
Interest on the convertible notes	$ 432	$ 504	$ 1,424	$ 1,510

Convertible Note Related Part_4

Convertible Note Related Party and Derivative Liabilities (Details 2) - Derivative Liabilities [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Beginning balance	$ 73,099	$ 61,682
Changes in Fair Value	(73,099)	11,417
Ending balance	$ 0	$ 73,099

Convertible Note Related Part_5

Convertible Note Related Party and Derivative Liabilities (Details 3)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Minimum [Member]
Expected term	3 months	1 year 29 days
Maximum [Member]
Expected term	4 months 20 days	1 year 2 months 19 days
Commitment Date [Member]
Expected term	1 year
Related Party Debt [Member]
Expected dividends	0%	0%
Risk free interest rate	2.22%	1.06%
Expected volatility	101.56%
Expected term	0 years
Related Party Debt [Member] | Minimum [Member]
Expected volatility		181%
Expected term		8 months 1 day
Related Party Debt [Member] | Maximum [Member]
Expected volatility		182%
Expected term		8 months 26 days
Related Party Debt [Member] | Commitment Date [Member]
Expected dividends	0%
Risk free interest rate	1.33%
Related Party Debt [Member] | Commitment Date [Member] | Minimum [Member]
Expected volatility	101%
Expected term	11 months 1 day
Related Party Debt [Member] | Commitment Date [Member] | Maximum [Member]
Expected volatility	103%
Expected term	1 year

Convertible Note Related Part_6

Convertible Note Related Party and Derivative Liabilities (Details Narrative) - USD ($)	1 Months Ended			9 Months Ended		12 Months Ended
	Sep. 27, 2022	Sep. 27, 2017	Sep. 01, 2016	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Received proceeds totaling				$ 0	$ 100,000	$ 100,000
Cubesquare Llc [Member]
Received proceeds totaling		$ 15,000	$ 10,000
Ownership percentage			25%
Interest rate per annum		8%	8%	8%
Conversion, description		any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare	(i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender
Accounts payable and accrued liabilities related party				$ 0		$ 9,449
Principal amount - related party convertible note modified to 6% promissory note	$ 35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note	25,000
Accrued interest payable - related party convertible note modified to 6% promissory note	$ 10,873

Convertible Note and Derivati_3

Convertible Note and Derivative Liabilities (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Face value of certain convertible notes	$ 115,000	$ 115,000
Less: unamortized discount	0	(52,774)
Carrying value	115,000	62,226
Derivative Liabilities [Member]
Face value of certain convertible notes	80,000	80,000
Less: unamortized discount	0	(541)
Carrying value	$ 80,000	$ 79,459

Convertible Note and Derivati_4

Convertible Note and Derivative Liabilities (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Interest on the convertible notes	$ 2,319	$ 2,319	$ 6,881	$ 2,697
Amortization on debt discount	0	28,750	52,774	33,476
Total	2,319	31,069	59,655	115,505
Commitment [Member] Warrants [Member]
Interest on the convertible notes	1,613	1,916	4,787	4,485
Amortization on debt discount	0	9,029	541	26,793
Total	$ 1,613	$ 10,945	$ 5,328	$ 31,278

Convertible Note and Derivati_5

Convertible Note and Derivative Liabilities (Details 2) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Convertible Note and Derivative Liabilities (Tables)
Balance at beginning	$ 157,490	$ 92,803
Change in fair value	(131,036)	64,687
Balance at ending	$ 26,454	$ 157,490

Convertible Note and Derivati_6

Convertible Note and Derivative Liabilities (Details 3)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Expected dividend	0%	0%
Risk free interest	3.33%	0.39%
Commitment Date [Member] Convertible Notes [Member]
Expected dividend	0%
Risk free interest	0.18%
Expected volatility	307.10%
Expected term	2 years 1 month 6 days
Expected term	1 year
Commitment Dates Maximum [Member]
Risk free interest	1.65%
Expected volatility	173%
Commitment Dates Minimum [Member]
Risk free interest	1.42%
Expected volatility	154%
Minimum [Member]
Expected volatility	95%	203%
Expected term	3 months	1 year 29 days
Maximum [Member]
Expected volatility	101%	301%
Expected term	4 months 20 days	1 year 2 months 19 days

Convertible Note and Derivati_7

Convertible Note and Derivative Liabilities (Details 4) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Convertible Note and Derivative Liabilities (Tables)
Face value of certain convertible notes	$ 115,000	$ 115,000
Less: unamortized discount	0	(52,774)
Carrying value	$ 115,000	$ 62,226

Convertible Note and Derivati_8

Convertible Note and Derivative Liabilities (Details 5) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Convertible Note and Derivative Liabilities (Tables)
Interest on the Quick notes	$ 2,319	$ 2,319	$ 6,881	$ 2,697
Day one loss associated with derivatively liability	0	0	0	79,332
Amortization on debt discount	0	28,750	52,774	33,476
Total	$ 2,319	$ 31,069	$ 59,655	$ 115,505

Convertible Note and Derivati_9

Convertible Note and Derivative Liabilities (Details 6) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Balance at ending	$ 26,454	$ 157,490
Warrants [Member] | Convertible Note June [Member]
Derivative liability associated with convertible note on commitment date		51,009
Derivative liability associated with warrants on commitment date		143,323
Change in fair value - convertible note	52,035	(21,597)
Change in fair value - warrants	82,315	2,633
Balance at ending	$ 309,718	$ 175,368

Convertible Note and Derivat_10

Convertible Note and Derivative Liabilities (Details 7)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Expected dividend	0%	0%
Risk free interest	3.33%	0.39%
Convertible Notes [Member]
Expected dividend	0%	0%
Risk free interest	1.28%	0.43%
Expected volatility	101.40%	215.70%
Expected term	0 years	5 months 12 days
Commitment Date [Member] Convertible Notes [Member]
Expected dividend	0%
Risk free interest	0.18%
Expected volatility	307.10%
Expected term	1 year
Warrants [Member]
Expected dividend	0%	0%
Risk free interest	3.76%	0.82%
Expected volatility	208.90%	200.90%
Expected term	3 years 8 months 12 days	4 years 5 months 12 days
Commitment And Warrants [Member]
Expected dividend	0%
Risk free interest	0.65%
Expected volatility	201.70%
Expected term	5 years

Convertible Note and Derivat_11

Convertible Note and Derivative Liabilities (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended		12 Months Ended
	Feb. 19, 2020	Dec. 31, 2019	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jun. 15, 2021
Received proceeds totaling			$ 0	$ 100,000	$ 100,000
Derivative Liabilities [Member]
Received proceeds totaling		$ 70,000
Interest rate per annum	8%	8%
Conversion description	we issued and sold in a private offering an 8% convertible note in the principal amount of $10,000. The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance	convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00
Accounts payable and accrued liabilities related party			17,656		$ 12,869
Derivative liability convertible notes			80,000
Derivative liabilities			$ 72,689
Principal amount						$ 115,000
Total investment						100,000
Obligation of payment						$ 2,000

Unsecured ShortTerm Advance fro

Unsecured ShortTerm Advance from Third Party (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Unsecured ShortTerm Advance from Third Party (Details Narrative)
Commercial Paper	$ 100,000	$ 100,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 27, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 27, 2017	Sep. 01, 2016
Due to related party		$ 13,672		$ 13,672		$ 10,674
Cubesquare Llc [Member]
Due to related party		$ 50,000		$ 50,000			$ 10,000
Interest rate per annum		8%		8%					8%	8%
Interest expense		$ 997	$ 1,008	$ 2,981	$ 2,991
Principal amount - related party convertible note modified to 6% promissory note	$ 35,873
Aggregate principal amount - related party convertible note modified to 6% promissory note	25,000
Accrued interest payable - related party convertible note modified to 6% promissory note	$ 10,873
Ido Merfeld [Member]
Due to related party		50,000		50,000			21,000	$ 1,169
Accounts payable and accrued liabilities		1,169		1,169		10,674
Advances amount				71,000		71,000
Jonah Meer [Member]
Due to related party		135,000		135,000			$ 70,000
Accounts payable and accrued liabilities		$ 16,000		16,000		16,900
Additional advances received				62,500
Payment of advances				900		11,575
Advances amount				$ 267,500		$ 205,000

Intellectual Property License_2

Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative)
License issue fee	$ 25,000
Default payment interest charges, percentage	10%
Annual license maintenance fee	$ 25,000
Earned royalty, percentage	2%
Royalty expense, first quarter	$ 500,000
Royalty expense, second quarter	1,000,000
Royalty expense, third quarter	2,000,000
Licence expense	$ 18,750	$ 18,750
Sublicense consideration, percent	15%

Stock Plan (Details)

Stock Plan (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Research and Development Expense [Member]
Stock option compensation allocated expenses	$ 0	$ 0	$ 0	$ 6,200

Stock Plan (Details 1)

Stock Plan (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Stock Plan
Shares Outstanding, beginning of period	4,098,332	3,276,666
Shares, Granted	0	975,000
Shares, exercised	$ 0	$ 0
Shares, Canceled/forfeited	(50,000)	(153,334)
Shares Outstanding, end of the period	4,048,332	4,098,332
Shares Options exercisable, end of period	4,048,332	4,098,332
Weighted Average Shares Exercise Price, Outstanding, beginning of period	$ 2	$ 1.98
Weighted Average Shares Exercise Price, Granted	0	2
Weighted Average Shares Exercise Price, Exercised	0	0
Weighted Average Exercise Price, Canceled/forfeited	0	2
Weighted Average Exercise Price, Options exercisable, end of period	2	2
Weighted Average Exercise Price, Weighted average fair value of options granted	$ 2	$ 1.98
Outstanding, Weighted Average Remaining Contractual Life, beginning of period	3 years 29 days	3 years 3 months 10 days
Outstanding, Weighted Average Remaining Contractual Life, enf of period	2 years 3 months 14 days	3 years 29 days
Options exercisable, Weighted Average Remaining Contractual Life, end of period	2 years 3 months 14 days	3 years 29 days

Stock Plan (Details Narrative)

Stock Plan (Details Narrative) - USD ($)

1 Months Ended

2 Months Ended

3 Months Ended

9 Months Ended

Feb. 10, 2021

Dec. 10, 2020

Feb. 10, 2020

Dec. 10, 2019

Dec. 10, 2018

Apr. 16, 2022

Dec. 22, 2021

Jun. 25, 2019

Sep. 30, 2022

Sep. 30, 2022

Sep. 30, 2022

Jan. 31, 2021

Jul. 15, 2020

Stock Options Granted To Employees [Member]

Granted an option to purchase of common stock

100,000

10,000

6,666

33,334

Weighted average excercise price

$ 2

$ 2

Description of services agreement

On December 10, 2020, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share and are immediately exercisable

On December 10, 2019, the Board awarded an employee, the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2021 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise. On March 23, 2020, the Company accelerated the vesting provision to provide for the immediate vesting of such options. Such options expire on March 23, 2023.

On December 10, 2018, the Board awarded an employee the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise. On March 23, 2020, the Company accelerated the vesting provision to provide for the immediate vesting of such options. 33,333 of such shares subject to the option were forfeited unexercised on December 10, 2021. The remaining option expires on March 23, 2023

Unrecognized compensation

$ 0

Stock Options Granted To Science Advisor And Business Advisors [Member]

Granted an option to purchase of common stock

50,000

Weighted average excercise price

$ 2

$ 2

Expiry date

February 10, 2024

February 10, 2023

Unvested options

25,000

25,000

25,000

Share exercisable

25,000

Stock Options Granted To Officers [Member]

Granted an option to purchase of common stock

100,000

10,000

325,000

100,000

Weighted average excercise price

$ 2

$ 2

Description of services agreement

On December 10, 2020, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share and are immediately exercisable

On December 10, 2019, the Board awarded an employee, the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2021 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise. On March 23, 2020, the Company accelerated the vesting provision to provide for the immediate vesting of such options. Such options expire on March 23, 2023

On December 22, 2021, under the Plan, the Board awarded an employee, an immediately exercisable three-year stock option to purchase 325,000 shares of the common stock of the Company at an exercise price of $2.00 per share

On June 25, 2019, the Company appointed John N. Bonfiglio, PhD as its chief operating officer, effective July 1, 2019. As compensation, Dr. Bonfiglio was granted a three-year stock option to purchase 100,000 shares of common stock at an exercise price of $2.00 per share, 50,000 of which shares vested upon grant and 25,000 shares vested on each of July 1, 2020 and July 1, 2021, provided Dr. Bonfiglio was in the employ of the Company on such dates. Mr. Bonfiglio was terminated as chief operating officer as of November 30, 2019. Accordingly, all unvested stock options terminated on such date. In January 2021, 50,000 vested options were forfeited

Capital Stock (Details)

Capital Stock (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Capital Stock
Warrants Outstanding Beginning	295,000	180,000
Warrants Granted	0	115,000
Warrants, canceled/forfieted	0	0
Warrants Exercised	0	0
Warrants Outstanding Ending	295,000	295,000
Weighted Average Exercise Price Outstanding Beginning	$ 1	$ 1
Weighted Average Exercise Price Granted	0	1
Weighted Average Exercise Price Canceled/Forfeited	0	0
Weighted Average Exercise Price Exercised	0	0
Weighted Average Exercise Price Outstanding End	$ 295,000	$ 1

Capital Stock (Details Narrativ

Capital Stock (Details Narrative) - $ / shares	1 Months Ended	9 Months Ended
	Jun. 15, 2021	Sep. 30, 2022	Dec. 31, 2021
Common Stock, Shares Authorized		100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Common stock exercise price per share	$ 1
Common Stock, Shares, Issued		13,289,789	13,289,789
Common Stock, Shares, Outstanding		13,289,789	13,289,789
Number of new share issued	115,000
Preferred Stock, Shares Authorized		10,000	10,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Preferred Stock, Shares Issued		2,000	2,000
Preferred Stock, Shares Outstanding		2,000	2,000
Series A, Preferred Stock
Preferred Stock, Shares Authorized		10,000	10,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Preferred Stock, Shares Issued		2,000	2,000
Preferred Stock, Shares Outstanding		2,000	2,000
Preferred Stock price per share		$ 1